The 11th batch of centralized drug procurement work has been launched

On July 15th, the National Healthcare Security Administration announced that the 11th batch of national organized drug centralized procurement work has been launched recently. After three-stage screening, 55 varieties have been included in the scope of the 11th batch of centralized procurement reporting.

The person in charge of the relevant department of the National Medical Insurance Administration introduced that the 11th batch of centralized procurement of drugs organized by the state has completed the selection of the intended procurement varieties, and the reporting work for medical institutions will soon be carried out. The overall procurement rules will adhere to the principles of "stabilizing clinical practice, ensuring quality, preventing bid rigging, and combating internal competition".

Adhere to the principle of "centralized procurement of non new drugs and non centralized procurement of new drugs", and scientifically determine the procurement varieties. Centralized procurement drugs are varieties that have been on the market for many years, have passed the patent protection period, and are produced by multiple companies. In other words, only clinically mature "old drugs" will be included in the scope of centralized procurement, and innovative drugs will not be included in centralized procurement.

This centralized procurement protects the innovation enthusiasm of the industry and excludes varieties that have entered the medical insurance through negotiations and are still within the agreement period. The market size conditions have been increased, and it is stipulated that in 2024, varieties with a procurement amount less than 100 million yuan on the centralized pharmaceutical procurement platforms of various provinces will not be included in the procurement scope. Based on the clinical usage characteristics and the opinions of relevant departments and experts, some key managed antibiotics and drugs with frequent adverse reactions are temporarily not included in the scope of this centralized procurement.

Medical device approval

Xinhua Pharmaceutical subsidiary's products have obtained Class III medical device registration certificates

On July 15th, Xinhua Pharmaceutical (000756. SZ) announced that its subsidiary Shandong Xinhua Health Technology Co., Ltd. recently received the "Medical Device Registration Certificate of the People's Republic of China" issued by the National Medical Products Administration. The product name is sterile physiological saline nursing solution for contact lenses, and the registration certificate number is National Medical Device Approval 20253161329. This product is applicable to the washing of hard contact lens and soft contact lens (including silicon hydrogel soft hydrophilic contact lens).

Sanyou Medical: JAZZSystem Spinal Internal Fixation Connector System Obtained Medical Device Registration Certificate

On July 15th, Sanyou Medical (688085. SH) announced that the registration application for the three types of medical devices "JAZZSystem Spinal Internal Fixation Connector System" submitted by the company's holding company, French Implant, has been approved for listing. This product is suitable for posterior spinal internal fixation surgery in thoracolumbar spine (T1-L5), and can be used in conjunction with components of the same series of spinal internal fixation systems to provide bundled fixation. Implant is a French orthopedic listed company controlled by the company, specializing in the research and sales of spinal internal fixation tension band products.

Financial report disclosure

Baicheng Pharmaceutical expects a year-on-year decrease of 95.53% to 100% in net profit for the first half of the year

On the evening of July 15th, Baicheng Pharmaceutical released its semi annual performance forecast for 2025, expecting a net profit attributable to shareholders of the listed company of 0-6 million yuan in the first half of 2025, a year-on-year decrease of 95.53% -100%. The net profit for the same period last year was 134 million yuan.

Kanglong Huacheng's net profit for the first half of the year is expected to decrease by 36% to 39% year-on-year

On July 15th, Kanglong Huacheng released its interim performance forecast, expecting a net profit attributable to shareholders of the listed company in the first half of the year of 6791.758 million yuan to 712.577 million yuan, a year-on-year decrease of 36% to 39%; It is expected that the net profit attributable to shareholders of the listed company after deducting non recurring gains and losses in the first half of the year will be 624.2831 million yuan to 647.5772 million yuan, a year-on-year increase of 34% to 39%. Reason for change: In the context of sustained improvement in the main business, mainly due to the decrease in non recurring gains and losses, the net profit attributable to shareholders of the listed company decreased by 36% -39% compared to the same period last year.

capital market

China Biopharmaceutical fully acquires Lixin Pharmaceutical

On July 15th, China Biopharmaceutical announced on the Hong Kong Stock Exchange that on July 15th, 2025 (after trading hours), the company (through the buyer) fully acquired Lixin Pharmaceutical and entered into a sale and purchase agreement with the seller, Lixin Pharmaceutical, and Ying Qin Zang. According to this agreement, the buyer has agreed to purchase and the seller has agreed to sell 95.09% equity of Lixin Pharmaceutical for consideration. As of the date of this announcement, the buyer holds 4.91% equity in Lixin Pharmaceutical. After the delivery, Lixin Pharmaceutical will become an indirect wholly-owned subsidiary of the company. The consideration shall not exceed 950.92 million US dollars. Excluding the estimated cash and bank deposits of approximately $450 million from Lixin Pharmaceutical Group on the delivery date, the net payment to be made by the buyer for the acquisition is approximately $500.9 million.

Kaici Medical has completed a financing of millions of yuan

On July 15th, Chongqing Kaici Medical Technology Co., Ltd. (hereinafter referred to as "Kaici Medical") recently completed a multi million yuan financing round. This round of financing is jointly invested by Chongqing Science and Technology Financial Service Center, Chongqing Mingyue Lake Private Equity Investment Fund, and Mingyue Lake Intelligent Technology Development Co., Ltd. This investment is also the first joint investment cooperation among the three institutions. The funds raised in this round will be used for the mass production and market expansion of the company's full maglev series products, and to accelerate the development process of multi pipeline full maglev products.

Industry Events

Baxdrostat achieved primary and all secondary endpoints in the BaxHTN Phase III clinical trial for patients with uncontrolled or refractory hypertension

On July 14th, AstraZeneca announced that its Baxdrostat has achieved both primary and all secondary endpoints in the BaxHTN Phase III clinical trial for patients with uncontrolled or refractory hypertension. According to the positive results of the BaxHTN Phase III trial, both doses (2 mg and 1 mg) of Baxdrostat showed statistically and clinically significant reductions in sitting systolic blood pressure (SBP) compared to placebo at 12 weeks of treatment. The trial also successfully achieved all secondary endpoints. Uncontrolled or refractory hypertension patients received Baxdrostat or placebo treatment on the basis of standard treatment. Baxdrostat has good overall safety and tolerability.

The research data will be submitted to regulatory agencies worldwide and presented at the latest breakthrough research session of the European Society of Cardiology (ESC) annual meeting in August 2025.

Weight loss of 19.2%, Hengrui Pharmaceutical discloses the results of a phase III weight loss study on GLP-1 drugs in China

On July 15th, Hengrui Pharmaceutical and Kailera Therapeutics announced that the phase III clinical trial (HRS9531-301) of GLP-1/GIP dual receptor agonist HRS9531 injection for the treatment of obese or overweight subjects in China achieved positive top line results. Compared with placebo, all dose groups (2 mg, 4 mg, 6 mg) of HRS9531 achieved superiority in the common primary endpoint and all key secondary endpoints. In addition, the results showed that the average weight loss in the HRS9531 treatment group was as high as 19.2%. Hengrui Pharmaceutical plans to submit a new drug application (NDA) for HRS9531 injection for long-term weight management in China in the near future, and Kailera is advancing the global clinical research and development of HRS9531 (KAI-9531).

Public opinion warning

Ruikang Pharmaceutical Director Han Chunlin Resigns

Recently, Ruikang Pharmaceutical Group Co., Ltd. announced that Han Chunlin, a director and vice president of the company, has decided to resign from his position as a director, vice president, and all other positions in the company and its subsidiaries due to personal reasons. After resigning, he will no longer hold any positions in the company and its holding subsidiaries.